Follow-up of Toxoplasmosis during Pregnancy: Ten-Year Experience in a University Hospital in Southern Brazil

Abstract

Objective To describe a population of pregnant women diagnosed with toxoplasmosis and their respective newborns, describing the hospital protocol for treatment and follow-up.

Methods Retrospective cohort of pregnant women with acute toxoplasmosis infection and risk of transplacental transmission who were sent to the Fetal Medicine Group of Hospital de Clínicas de Porto Alegre (HCPA) between - January 1, 2006 and December 31, 2016. All patients with confirmed disease were included. The diagnostic protocol and treatment were applied; a polymerase chain reaction (PCR) analysis of the amniotic fluid was used to diagnose toxoplasmosis and determine the treatment. The newborns were followed up at the pediatric outpatient clinic specializing in congenital infection. The patients who were not followed up or were not born in the HCPA were excluded.

Results A total of 65 patients were confirmed to have gestational toxoplasmosis; 40 performed amniocentesis, and 6 (15%) were identified as having positive PCR in the amniotic fluid. In five of those cases, this result associated with the gestational age defined the triple therapy during pregnancy, and in one case, it defined the monotherapy (advanced gestational age). A total of 4 of these newborns were treated from birth with triple therapy for 10 months, 1 was not treated (due to maternal refusal), and 1 progressed to death within the first 54 hours of life due to complications of congenital toxoplasmosis. Of the 34 remaining cases with a negative PCR, 33 were treated with monotherapy and 1 was treated with triple therapy (ultrasound findings); of these children, 9 (26.5%) presented negative immunoglobulin G (IgG), 24 (70.6%) presented positive IgG (but none presented positive immunoglobulin M [IgM]), and 1 (2,9%) presented alterations compatible with congenital disease and started treatment with the triple therapy soon after birth. Out of the total sample of 60 patients, among the 25 who did not perform amniotic fluid PCR, 5 were treated with triple therapy (ultrasound findings/prior treatment) and 20 patients were submitted to monotherapy; only two newborns underwent treatment for congenital toxoplasmosis. Among the 65 cases of gestational toxoplasmosis, 6 (9,2%) children had a diagnosis of congenital toxoplasmosis, and 2 patients with triple therapy felt severe adverse effects of the medications.

Conclusions The present study suggests that research on PCR screening of the amniotic fluid may be useful to identify patients with a higher potential for fetal complications, who may benefit from the poly-antimicrobial treatment. Patients with negative PCR results must continue to prevent fetal infection with monotherapy, without risk of fetal or maternal impairment.

Resumo

Objetivo Descrever uma população de pacientes diagnosticadas com toxoplasmose na gestação e seus respectivos recém-nascidos, relatando o protocolo do hospital durante o tratamento e seguimento.

Métodos Coorte retrospectiva de gestantes com infecção aguda por toxoplasmose e risco de transmissão transplacentária, encaminhadas para acompanhamento pelo Grupo de Medicina Fetal do Hospital de Clínicas de Porto Alegre (HCPA) entre 1^o de janeiro de 2006 e 31 de dezembro de 2016. Todas as pacientes com doença confirmada foram incluídas. O protocolo de diagnóstico e tratamento foi aplicado; uma análise da reação em cadeia da polimerase (RCP) no líquido amniótico foi utilizada para diagnosticar a toxoplasmose e determinar o tratamento. Os recém-nascidos foram acompanhados no ambulatório de pediatria especializado em infecções congênitas. Pacientes que não foram seguidas ou cujo parto não foi feito no hospital foram excluídas.

Resultados A toxoplasmose gestacional foi confirmada em 65 pacientes; 40 realizaram amniocentese, e 6 (15%) foram identificadas com RCP positiva no líquido amniótico. Este resultado associado à idade gestacional definiu a terapia tríplice durante a gestação em 5 casos, e a monoterapia em 1 caso (por idade gestacional avançada). Quatro destas crianças foram tratadas desde o nascimento com terapia tríplice por 12 meses, 1 não foi tratada (por recusa materna), e 1 evoluiu com óbito dentro das primeiras 54 horas de vida devido a complicações da toxoplasmose congênita. Dos 34 casos remanescentes com RCP negativa, 33 foram tratados com monoterapia, e 1 foi tratado com terapia tríplice (por achados ultrassonográficos); destes recém-nascidos, 9 (26,5%) tiveram imunoglobulina G (IgG) negativa, 24 (70,6%) tiveram IgG positiva, mas nenhum apresentou imunoglobulina M (IgM) positiva, e 1 (2,9%) apresentou alterações compatíveis com doença congênita e iniciou a terapia tríplice logo após o nascimento. Entre as 25 pacientes que não fizeram RCP no líquido amniótico, 5 foram tratadas com terapia tríplice (por achados ultrassonográficos/tratamento prévio) e 20 receberam monoterapia; somente 2 recém-nascidos receberam tratamento para toxoplasmose congênita. Entre os 65 casos de toxoplasmose gestacional, 6 (9,2%) recém-nascidos tiveram o diagnóstico de toxoplasmose congênita. Um total de 2 pacientes submetidas à terapia tríplice apresentaram efeitos adversos severos das medicações utilizadas.

Conclusão Este estudo sugere que a triagem da RCP para toxoplasmose do líquido amniótico pode ser útil no rastreamento de pacientes com maior potencial para complicações fetais, que podem se beneficiar do tratamento poli antimicrobiano. Pacientes com RCP negativa devem continuar a prevenir a infecção fetal com monoterapia, sem risco de comprometimento fetal ou materno.

Keywords

toxoplasmosis - congenital infection - fetal infection - congenital toxoplasmosis - pharmacodermia

Palavras-chave

toxoplasmose - infecção congênita - infecção fetal - toxoplasmose congênita - farmacodermia

Contributors

All of the authors contributed with the project and data interpretation, the writing of the article, the critical review of the intellectual content, and with the final approval of the version to be published.

• References

• 1 de Quadros RM, da Rocha GC, Romagna G, de Oliveira JP, Ribeiro DM, Marques SMT. Toxoplasma gondii seropositivity and risk factors in pregnant women followed up by the Family Health Strategy. Rev Soc Bras Med Trop 2015; 48 (03) 338-342 . Doi: 10.1590/0037-8682-0233-2014
• 2 Souza CdeO, Tashima NT, Silva MA, Tumitan ARP. [Cross-sectional study on toxoplasmosis among female students on a university course in the Presidente Prudente region, State of São Paulo]. Rev Soc Bras Med Trop 2010; 43 (01) 59-61 . Doi: 10.1590/S0037-86822010000100013
• 3 Pessanha TM, Carvalho M, Pone MVS, Gomes Junior SC. Abordagem diagnóstica e terapêutica da toxoplasmose em gestantes e as repercussões no recém-nascido. Rev Paul Pediatr 2011; 29: 341-347 . Doi: 10.1590/S0103-05822011000300006
• 4 Ministério da Saúde. Secretaria de Atenção à Saúde. Departamento de Ações Programáticas Estratégicas. Atenção à Saúde do Recém-Nascido: Guia para os Profissionais de Saúde. 2a ed. Brasília, DF: Ministério da Saúde; 2014
• 5 Lehmann LM, Santos PC, Scaini CJ. Evaluation of pregnant and postpartum women's knowledge about toxoplasmosis in Rio Grande – RS, Brazil. Rev Bras Ginecol Obstet 2016; 38 (11) 538-544 . Doi: 10.1055/s-0036-1593970
• 6 Mozzatto L, Procianoy RS. Incidence of congenital toxoplasmosis in southern Brazil: a prospective study. Rev Inst Med Trop São Paulo 2003; 45 (03) 147-151 . Doi: 10.1590/S0036-46652003000300006
• 7 Furtado JM, Smith JR, Belfort Jr R, Gattey D, Winthrop KL. Toxoplasmosis: a global threat. J Glob Infect Dis 2011; 3 (03) 281-284 . Doi: 10.4103/0974-777X.83536
• 8 Fochi MML, Baring S, Spegiorin LCJF. , et al. Prematurity and low birth weight did not correlate with anti-toxoplasma gondii maternal serum profiles - a Brazilian report. PLoS One 2015; 10 (07) e0132719 . Doi: 10.1371/journal.pone.0132719
• 9 Soares JA, Carvalho SF, Caldeira AP. Profile of pregnant women and children treated at a reference center for congenital toxoplasmosis in the northern state of Minas Gerais, Brazil. Rev Soc Bras Med Trop 2012; 45 (01) 55-59 . Doi: 10.1590/S0037-86822012000100011
• 10 Lopes-Mori FMR, Mitsuka-Breganó R, Bittencourt LHFB. , et al. Gestational toxoplasmosis in Paraná State, Brazil: prevalence of IgG antibodies and associated risk factors. Braz J Infect Dis 2013; 17 (04) 405-409 . Doi: 10.1016/j.bjid.2012.12.003
• 11 Wilking H, Thamm M, Stark K, Aebischer T, Seeber F. Prevalence, incidence estimations, and risk factors of Toxoplasma gondii infection in Germany: a representative, cross-sectional, serological study. Sci Rep 2016; 6: 22551 . Doi: 10.1038/srep22551
• 12 Di Mario S, Basevi V, Gagliotti C. , et al. Prenatal education for congenital toxoplasmosis. Cochrane Database Syst Rev 2015; (10) CD006171 . Doi: 10.1002/14651858.CD006171.pub4
• 13 Ministério da Saúde. Secretaria de Atenção à Saúde. Departamento de Ações Programáticas Estratégicas. Gestação de Alto Risco: Manual Técnico. 5ª ed. Brasília, DF: Editora do Ministério da Saúde; 2012
• 14 Federação Brasileira de Ginecologia e Obstetrícia. Manual de Gestação de Alto Risco. São Paulo, SP: FEBRASGO; 2011 https://www.febrasgo.org.br/images/arquivos/manuais/Manuais_Novos/gestacao_alto-risco_30-08.pdf . Accessed November 16, 2017.
• 15 McLeod R, Lykins J, Noble AG. , et al. Management of congenital toxoplasmosis. Curr Pediatr Rep 2014; 2: 166-194 . Doi: 10.1007/s40124-014-0055-7
• 16 Flegr J, Prandota J, Sovičková M, Israili ZH. Toxoplasmosis--a global threat. Correlation of latent toxoplasmosis with specific disease burden in a set of 88 countries. PLoS One 2014; 9 (03) e90203 . Doi: 10.1371/ journal.pone.0090203
• 17 Wallon M, Peyron F, Cornu C. , et al. Congenital toxoplasma infection: monthly prenatal screening decreases transmission rate and improves clinical outcome at age 3 years. Clin Infect Dis 2013; 56 (09) 1223-1231 . Doi: 10.1093/cid/cit032
• 18 American College of Obstetricians and Gynecologists. Practice bulletin no. 151: Cytomegalovirus, parvovirus B19, varicella zoster, and toxoplasmosis in pregnancy. Obstet Gynecol 2015; 125 (06) 1510-1525 . Doi: 10.1097/01.AOG.0000466430.19823.53
• 19 Tanimura K, Nishikawa A, Tairaku S. , et al. The IgG avidity value for the prediction of Toxoplasma gondii infection in the amniotic fluid. J Infect Chemother 2015; 21 (09) 668-671 . Doi: 10.1016/j.jiac.2015.05.013
• 20 Capobiango JD, Monica TC, Ferreira FP. , et al. Evaluation of the Western blotting method for the diagnosis of congenital toxoplasmosis. J Pediatr (Rio J) 2016; 92 (06) 616-623 . Doi: 10.1016/j.jped.2016.02.014
• 21 Pena LT, Discacciati MG. Importância do teste de avidez da imunoglobulina G (IgG) anti-Toxoplasma gondii no diagnóstico da toxoplasmose em gestantes. Rev Inst Adolfo Lutz 2013; 72: 117-123 . Doi: 10.18241/0073-98552013721551
• 22 Prusa AR, Kasper DC, Pollak A, Olischar M, Gleiss A, Hayde M. Amniocentesis for the detection of congenital toxoplasmosis: results from the nationwide Austrian prenatal screening program. Clin Microbiol Infect 2015; 21 (02) 191.e1-191.e8 . Doi: 10.1016/j.cmi.2014.09.018
• 23 Bernardo WM, Chinzon M, Chaves FGB. Is sulfadiazine alone equivalent (benefit and harm) to spiramycin to treat acute toxoplasmosis in the first trimester of pregnancy?. Rev Assoc Med Bras (1992) 2015; 61 (06) 495-496 . Doi: 10.1590/1806-9282.61.06.495
• 24 Dhombres F, Friszer S, Maurice P. , et al. Prognosis of fetal parenchymal cerebral lesions without ventriculomegaly in congenital toxoplasmosis infection. Fetal Diagn Ther 2017; 41 (01) 8-14 . Doi: 10.1159/000445113
• 25 Li XL, Wei HX, Zhang H, Peng HJ, Lindsay DS. A meta analysis on risks of adverse pregnancy outcomes in Toxoplasma gondii infection. PLoS One 2014; 9 (05) e97775 . Doi: 10.1371/journal.pone.0097775
• 26 Wei HX, Wei SS, Lindsay DS, Peng HJ. A systematic review and meta-analysis of the efficacy of anti-Toxoplasma gondii medicines in humans. PLoS One 2015; 10 (09) e0138204 . Doi: 10.1371/journal.pone.0138204
• 27 Teixeira LE, Kanunfre KA, Shimokawa PT. , et al. The performance of four molecular methods for the laboratory diagnosis of congenital toxoplasmosis in amniotic fluid samples. Rev Soc Bras Med Trop 2013; 46 (05) 584-588 . Doi: 10.1590/0037-8682-0095-2013
• 28 Filisetti D, Yera H, Villard O. , et al. Contribution of neonatal amniotic fluid testing to diagnosis of congenital toxoplasmosis. J Clin Microbiol 2015; 53 (05) 1719-1721 . Doi: 10.1128/JCM.02358-14
• 29 Maldonado YA, Read JS. ; COMMITTEE ON INFECTIOUS DISEASES. Diagnosis, treatment, and prevention of congenital toxoplasmosis in the United States. Pediatrics 2017; 139 (02) e20163860 . Doi: 10.1542/peds.2016-3860
• 30 Pomares C, Montoya JG. Laboratory diagnosis of congenital toxoplasmosis. J Clin Microbiol 2016; 54 (10) 2448-2454 . Doi: 10.1128/JCM.00487-16
• 31 Lago EG, Oliveira AP, Bender AL. Presence and duration of anti-Toxoplasma gondii immunoglobulin M in infants with congenital toxoplasmosis. J Pediatr (Rio J) 2014; 90 (04) 363-369 . Doi: 10.1016/j.jped.2013.12.006
• 32 de Oliveira Azevedo CT, do Brasil PE, Guida L, Lopes Moreira ME. Performance of polymerase chain reaction analysis of the amniotic fluid of pregnant women for diagnosis of congenital toxoplasmosis: a systematic review and meta-analysis. PLoS One 2016; 11 (04) e0149938 . Doi: 10.1371/journal.pone.0149938
• 33 Rajapakse S, Weeratunga P, Rodrigo C, de Silva NL, Fernando SD. Prophylaxis of human toxoplasmosis: a systematic review. Pathog Glob Health 2017; 111 (07) 333-342 . Doi: 10.1080/20477724.2017.1370528
• 34 Avci ME, Arslan F, Çiftçi Ş. , et al. Role of spiramycin in prevention of fetal toxoplasmosis. J Matern Fetal Neonatal Med 2016; 29 (13) 2073-2076 . Doi: 10.3109/14767058.2015.1074998
• 35 Rajapakse S, Chrishan Shivanthan M, Samaranayake N, Rodrigo C, Deepika Fernando S. Antibiotics for human toxoplasmosis: a systematic review of randomized trials. Pathog Glob Health 2013; 107 (04) 162-169 . Doi: 10.1179/2047773213Y.0000000094
• 36 Castro-Filice LS, Barbosa BF, Angeloni MB. , et al. Azithromycin is able to control Toxoplasma gondii infection in human villous explants. J Transl Med 2014; 12: 132 . Doi: 10.1186/1479-5876-12-132
• 37 Hotop A, Hlobil H, Gross U. Efficacy of rapid treatment initiation following primary Toxoplasma gondii infection during pregnancy. Clin Infect Dis 2012; 54 (11) 1545-1552 . Doi: 10.1093/cid/cis234
• 38 Cacoub P, Musette P, Descamps V. , et al. The DRESS syndrome: a literature review. Am J Med 2011; 124 (07) 588-597 . Doi: 10.1016/j.amjmed.2011.01.017